Edition:
United States

ValiRx PLC (VALX.L)

VALX.L on London Stock Exchange

2.55GBp
22 Mar 2017
Change (% chg)

-- (--)
Prev Close
2.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,147,723
52-wk High
17.30
52-wk Low
2.31

Latest Key Developments (Source: Significant Developments)

ValiRx Plc announces new Japanese patent grant
Thursday, 1 Oct 2015 02:00am EDT 

ValiRx Plc:Says that it has received patent approval by the Japanese Patent Office covering the means for diagnosing and monitoring of patients using biomarker testing for B-cell lymphomas and its prognostic outcome.  Full Article

ValiRx Plc says Subscription and Equity Swap
Wednesday, 16 Sep 2015 02:01am EDT 

ValiRx Plc:Says it has raised, in aggregate, £2,450,000, before expenses, through the subscription by YA Global Master SPV Ltd ("Yorkville") of 8,161,637 new ordinary shares at 30.018p per share pursuant to a subscription agreement between the Company and Yorkville.Says the Company has entered into an equity swap agreement (the "Equity Swap") with Yorkville concerning 6,430,872 of the Subscription Shares ("Swap Shares").Pursuant to the Equity Swap, in return for a payment by the Company to Yorkville of £1,000,000.  Full Article

ValiRx Plc announces collaboration and research studentship agreement
Thursday, 6 Aug 2015 02:00am EDT 

ValiRx Plc:Says agreement and signing of a new collaborative research project with Professor Paul Taylor, Director of Student Education and Professor of Chemical Education at School of Chemistry, University of Leeds.Collaboration will give ValiRx access to Professor Taylor's new research results, once he starts work on project.Research project will see PhD student develop project for three and half years under the guidance of Professor Taylor and Dr Suzanne Dilly, with Dilly acting as industrial supervisor for ValiRx to co-ordinate the programme between company and academic collaborators.  Full Article

ValiRx PLC announces re contract
Thursday, 7 May 2015 02:00am EDT 

ValiRx PLC:Says a contract has been secured with Admescope Ltd, for access to ValiRx's newly acquired 'TRAC' Finnish gene expression & biomarker technology.Admescope has agreed a global, non-exclusive license from ValiFinn to use the TRAC technology in its provision of toxicological testing services to drug discovery and development companies.  Full Article

More From Around the Web